We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes.
- Authors
Mous, R.; Savage, P.; Remmerswaal, E. B. M.; van Lier, R. A. W.; Eldering, E.; van Oers, M. H. J.
- Abstract
B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5+ B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fused anti-CD20 single-chain variable fragment (scFv) is used in combination with biotinylated MHC class I molecules containing CMV pp65 peptide (HLA/CMV). We demonstrate that B-CLL cells coated with this CD20-HLA/CMV complex can be lysed by autologous CMV-specific CTL with similar efficiency as B-CLL cells directly loaded with CMV peptide. Killing is HLA restricted and occurs at scFv CD20 concentrations of 100 ng ml−1 and HLA/CMV concentrations of 20 ng ml−1. Furthermore, complex-coated B-CLL cells induce both proliferation and cytokine production (interferon γ, tumour necrosis factor α and macrophage inflammatory protein−1 β) in CMV-specific CD8+ T cells. Hereby, a necessary step towards possible application of CD20-HLA/CMV complexes for immunotherapy of B-cell malignancies is constituted.Leukemia (2006) 20, 1096–1102. doi:10.1038/sj.leu.2404185; published online 23 March 2006
- Subjects
CYTOMEGALOVIRUS diseases; HERPESVIRUS diseases; LYMPHOCYTIC leukemia; LYMPHOPROLIFERATIVE disorders; B cells; HLA histocompatibility antigens; CD antigens
- Publication
Leukemia (08876924), 2006, Vol 20, Issue 6, p1096
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/sj.leu.2404185